A 12 Week Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort TM (40/4.5 Mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Asthmatic Children Aged Six to Eleven Years - SEEDLING 40/4.5

Trial Profile

A 12 Week Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort TM (40/4.5 Mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Asthmatic Children Aged Six to Eleven Years - SEEDLING 40/4.5

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2008

At a glance

  • Drugs Budesonide; Budesonide/formoterol; Formoterol
  • Indications Asthma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SEEDLING
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Jun 2008 New trial record.
    • 04 Jun 2008 sNAD submitted to FDA according to AstraZeneca media release.
    • 04 Jun 2008 Efficacy and safety results were reported at ATS 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top